CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients by Rihani, Ali et al.
RESEARCH ARTICLE
CASP8 SNP D302H (rs1045485) Is
Associated with Worse Survival in MYCN-
Amplified Neuroblastoma Patients
Ali Rihani1, Bram De Wilde1, Fjoralba Zeka1, Genevie`ve Laureys2,
Nadine Francotte3, Gian Paolo Tonini4, Simona Coco5, Rogier Versteeg6,
Rosa Noguera7, Johannes H. Schulte8,9,10,11,12, Angelika Eggert11,
Raymond L. Stallings13, Frank Speleman1, Jo Vandesompele1, Tom Van
Maerken1*
1. Center for Medical Genetics, Ghent University, Ghent, Belgium, 2. Department of Pediatric Hematology,
Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium, 3. De´partement de
pe´diatrie, he´mato-oncologie, SUHOPL- CHC (Service Universitaire d9He´matoOncologie Pe´diatrique Centre
Hospitalier Chre´tien) Espe´rance, St Nicolas Belgium, 4. Neuroblastoma Laboratory, Onco/Hematology
Laboratory, Department of Women’s and Children’s Health, University of Padua, Pediatric Research Institute,
Fondazione Citta` della Speranza, Padua, Italy, 5. Lung Cancer Unit, IRCCS (Istituto di Ricovero e Cura a
Carattere Scientifico), Azienda Ospedaliera Universitaria San Martino – IST (Istituto Nazionale per la Ricerca
sul Cancro), Genoa, Italy, 6. Departement of Human Genetics, Academic Medical Center, University of
Amsterdam, Amsterdam, the Netherlands, 7. Department of Pathology, Medical School, University of
Valencia, Valencia, Spain, 8. German Cancer Consortium (DKTK), Germany, 9. Translational Neuro-
Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen,
Germany, 10. German Cancer Research Center (DKFZ), Heidelberg, Germany, 11. Department of Pediatric
Oncology and Haematology, University Children’s Hospital Essen, Essen, Germany, 12. Centre for Medical
Biotechnology, University Duisburg-Essen, Essen, Germany, 13. Department of Molecular and Cellular
Therapeutics, Royal College of Surgeons in Ireland, and National Children9s Research Centre, Dublin, Ireland
*Corresponding Author Email: Tom.VanMaerken@UGent.be
Abstract
Background: Neuroblastoma is a pediatric cancer that exhibits a wide clinical
spectrum ranging from spontaneous regression in low-risk patients to fatal disease
in high-risk patients. The identification of single nucleotide polymorphisms (SNPs)
may help explain the heterogeneity of neuroblastoma and assist in identifying
patients at higher risk for poor survival. SNPs in the TP53 pathway are of special
importance, as several studies have reported associations between TP53 pathway
SNPs and cancer. Of note, less than 2% of neuroblastoma tumors have a TP53
mutation at diagnosis.
Patients and Methods:We selected 21 of the most frequently studied SNPs in the
TP53 pathway and evaluated their association with outcome in 500 neuroblastoma
patients using TaqMan allelic discrimination assays.
Results and Conclusion: We investigated the impact of 21 SNPs on overall
survival, event-free survival, age at diagnosis, MYCN status, and stage of the
disease in 500 neuroblastoma patients. A missense SNP in exon 10 of the CASP8
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gene SNP D302H was associated with worse overall and event-free survival in
patients with MYCN-amplified neuroblastoma tumors.
Background
Neuroblastoma (NB) is a complex and heterogeneous pediatric cancer that can
manifest with tumors that regress spontaneously, and also with tumors that
metastasize and acquire resistance to therapy, leading to severe illness and death
[1]. Currently, the treatment protocols depend on the risk stratification at
diagnosis, which in turn is based on the clinico-genetic features of the patient and
the tumor. The risk stratification system has been improved over the past decades
[2]; however, it remains imperative to further exploit the underlying biology of
clinico-genetic features of the disease for the sake of tailoring therapies to defined
patient populations. Inter-individual variability in response to therapy can result
from single nucleotide polymorphisms (SNPs) in critical genes involved in cell
cycle control and induction of apoptosis [3]. Some SNPs have proven their
usefulness in serving as prognostic markers in development of targeted therapies,
or defining patient populations in terms of potential response to conventional
therapies. One of the most critical genes that acts as a guardian of the genome and
also mediates response to therapy is TP53 [4]. TP53 is mutated in more than 50%
of human cancers [5]; however, less than 2% of NB tumors harbor a TP53
mutation at diagnosis [6]. This suggests that other players in the TP53 pathway
such as SNPs may play a role in NB.
Genetic polymorphisms in TP53 pathway components have been targeted for
personalizing current therapies and developing new treatment modalities [7].
However, only a limited number of studies have focused on the association
between SNPs in TP53 pathway genes and NB. Therefore, we selected 21 SNPs in
fifteen TP53 pathway associated genes (Table 1), which have been reported to be
involved in susceptibility to several cancer types. SNP selection was primarily
based on a study that identified potential SNPs involved in TP53 stress response
using publicly available genotypes and drug response data from the NCI60 human
tumor cell lines [8]. NCI60 is a well-characterized panel of 60 human cancer cell
lines from different cancer entities with publicly available anti-cancer drug
screening data [9] and genotype data from 100,000 SNPs in cancer related genes
[10, 11]. We expanded this selection to include SNPs in TP53 pathway associated
genes that have been reported elsewhere to be involved in cancer susceptibility
[4, 12–15]. The 21 SNPs are found in genes involved in DNA damage response,
apoptotic response, cell cycle regulation, direct regulation of TP53, or the TP53
gene itself (Table 1). We genotyped these SNPs in 500 NB cases and investigated
the association between these SNPs and overall and event-free survival, age at
diagnosis, MYCN status, and the stage of the disease of NB patients.
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Materials and Methods
Patients
The study group comprised 500 NB patients who were evaluated according to the
International NB Staging System (INSS) [16]. All patients included in this study
provided written informed consent for anonymous use of the samples for research
related to neuroblastoma biology. Approval for this study was granted by the
medical ethical committee of Ghent University Hospital. Registration number:
B670201111331.
Statistical methods
Comparisons of Kaplan-Meier survival curves between different genotype groups
were done using the log-rank test. Survival time was defined as the time from
diagnosis until death from the disease or until the date of the last follow-up of
living patients. Patient samples were divided into two groups based on SNP status
(wild-type versus homozygous or heterozygous for the minor allele).
Comparisons of age at diagnosis between the different groups were done using the
Mann-Whitney U test. Association of the SNPs with MYCN status or stage of the
disease was done using Pearson’s Chi-square test. Statistical tests were two-sided
Table 1. 21 SNPs in 15 p53 pathway genes.
Gene symbol Reference SNP ID Description Residue Ref Taqman assay ID
SNP
frequency
ATM rs1800054 missense C.G Ser49Cys [4] C___2283268_20 0.018
CASP8 rs1045485 missense G.C Asp302His [4] C___8823877_20 0.101
CDKN1A rs1801270 missense C.A Ser31Arg [4] C_____14977_20 0.092
TP53 rs1042522 missense C.G Pro72Arg [4] C___2403545_10 0.291
CCNG1 rs2069347 Intronic T.C [8] C___2000410_20 0.407
CD44 rs187115 Intronic G.A [8] C____779820_10 0.368
YWHAQ rs6734469 Intronic A.G [8] C__29724290_10 0.456
PIAS1 rs1027154 Intronic G.C [8] C___1935268_20 0.085
PPP2R2B rs319217 Intronic A.G [8] C___3065531_30 0.403
PPP2R2B rs319227 Intronic T.G [8] C____803346_10 0.361
CSE1L rs2426127 Intronic C.T [8] C__16230087_10 0.288
KDR rs2168945 Intronic T.G [8] C___1673863_10 0.350
MDM2 (285) rs117039649 Intronic G.C [12] 0.093
MDM2 (309) rs2279744 Intronic T.G [4] 0.376
MDM2 (344) rs1196333 Intronic T.A [13] 0.05
MDM2 (354) rs769412 Synonymous A.G [14] 0.076
MDM4 rs4245739 39UTR A.C [15] C__11623776_10 0.264
TP53 rs78378222 39UTR A.C [36] AHKASE2 0.050
CDKN1B rs34330 59 UTR T.C [4] C___2402292_10 0.244
TP73 rs2273953 59 UTR C.T [4] C__16180357_10 0.197
TP73 rs1801173 59 UTR C.T [4] C__16180356_10 0.169
doi:10.1371/journal.pone.0114696.t001
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and results with corrected p-values (q-values) ,0.05 were considered statistically
significant. All statistical analyses were conducted using SPSS version 20 software.
All statistical analyses were followed by Benjamini-Hochberg multiple testing
correction in R version 3.0.2 using ‘‘stats’’ statistical package.
SNP selection and genotyping
SNPs in potentially important TP53 pathway genes were selected from previously
reported studies [4, 8, 12–15]. The protein products of these genes function at
different levels of the TP53 pathway. MDM2 SNPs (285, 309, 344, and 354) were
genotyped by Sanger sequencing and the remaining 17 SNPs in TP53 pathway
genes were genotyped using the TaqMan allelic discrimination assay. NB tumor
DNA was first amplified using illustra GenomiPhi V2 DNA amplification kit (GE
Healthcare Life Sciences, Buckinghamshire UK) according to the manufacturer’s
protocol. Genotyping was carried out using 10 ng of amplified genomic DNA per
reaction, with 2.5 mL of 2X TaqMan Genotyping Master Mix and 160 nM primers
(Life Technologies, Merelbeke, Belgium) in a 5 mL reaction volume. All genotypes
were determined by endpoint calling on an ABI 7900 real-time PCR instrument
(Life Technologies, Merelbeke, Belgium). PCR cycling conditions were 50 C˚ for
2 min, 95 C˚ for 10 min, followed by 40 cycles of 92 C˚ for 15 s and 60 C˚ for 1 min.
Sanger sequencing was carried out by PCR amplification and subsequent
sequencing. The primers used for PCR amplification were tagged with universal
M13 sequencing tags (underlined): forward primer CACGACGTTGTAAAACG-
ACTGGCTTTGCGGAGGTT and reverse primer CAGGAAACAGCTATGACC-
TCGGAACGTGTCTGAACTT. The PCR was performed in a 25 ml reaction mix
using 20 ng of DNA, 1x KAPA2G buffer, 2.5 mM MgCl2, 0.2 mM dNTP mix,
0.5 mM forward and reverse primers, and 1 U KAPA2G Robust HotStart DNA
polymerase. PCR conditions were as follows: initial denaturation at 94 C˚ for
4 min, denaturation at 94 C˚ for 20 s, primer annealing at 68 C˚ for 15 s, and
extension at 72 C˚ for 1 min for 12 cycles. This was followed by another 34 cycles:
denaturation at 94 C˚ for 30 s, primer annealing at 55 C˚ for 30 s, and extension at
72 C˚ for 30 s. Finally, an extension step at 72 C˚ for 4 min was performed,
followed by cooling at 15 C˚ for 1 min. The size of the amplified PCR product was
verified using Caliper Labchip GX (PerkinElmer, Waltham, MA, USA). The
sequencing was done using Sanger DNA sequencing service (Genewiz, South
Plainfield, NJ, USA). The generated data was analyzed using Seqscape software
v.2.7 (Life Technologies, Ghent, Belgium). 18 SNPs were genotyped in 31 NB cell
lines (amplified and non-amplified DNA) to ensure the quality of the DNA
amplification procedure.
Reverse transcription quantitative polymerase chain reaction (RT-
qPCR)
RT-qPCR was performed on duplicate samples using 5 ng of template cDNA,
2.5 mL of 2x Soo Advanced Reaction Mix (Roche), and 0.25 mL of a 5 mM solution
CASP8 SNP D302H (rs1045485) in Neuroblastoma
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of each primer in a 5 mL total reaction volume. The PCR conditions were as
follows: 10 min at 95 C˚, followed by 45 cycles of denaturation (10 s at 95 C˚), and
elongation (45 s at 60 C˚) using LightCycler480 (Roche). Primers for caspase-8
and the reference genes (Alu-Sq, HMBS, HPRT1, SDHA, and UBC) were designed
using an in-house web tool (www.primerXL.org). The sequence of the primers can
be found in Table S1 in S1 File. Relative expression of caspase 8 was quantified
using Biogazelle’s qbase+ qPCR data-analysis software version 2.y [17]
Results
CASP8 SNP D302H and survival in NB patients
We used whole genome amplified DNA from tumors of 500 NB patients to
genotype 21 SNPs in fifteen TP53 pathway genes (Table 1) using hydrolysis probe
based qPCR genotyping assays for 17 SNPs, and Sanger sequencing for four
MDM2 SNPs (285, 309, 344, and 354). The clinical features of the patients are
shown in Table 2. The study population consisted mostly of European patients
from Caucasian origin. We first validated the approach by genotyping the SNPs
on whole genome amplified and non-amplified DNA from 31 NB cell lines, and
results showed that all SNPs were genotyped correctly (Table S2 in S1 File). In
patients, CASP8 SNP D302H was the only SNP that showed an association with
worse overall (OS) (p50.0006; multiple testing corrected p-value, q-value50.049)
and event-free survival (EFS) (p50.0002; multiple testing corrected p-value, q-
value50.042) in NB patients with MYCN amplification (Fig. 1, Table 3). The
stratified survival analyses of all the other SNPs are shown in table S3 in S1 File.
To confirm that there is no difference in the SNP status between the tumor and
the germline of the patients, we collected 41 representative blood samples from
the patients in our cohort and genotyped them using the same TaqMan assay for
the CASP8 SNP D302H. Our results show that all the 41 patients have exactly the
same SNP status in their blood as in their tumor (data not shown). This
additional analysis makes it highly unlikely that different SNP status exists in the
tumor compared to the blood of the patients. We performed also multivariate
Cox proportional hazard analysis and investigated the effect of CASP8 SNP
D302H on the survival of neuroblastoma patients taking into account the
different clinical covariates (stage of the disease, MYCN status, and the age at
diagnosis). Our results show that CASP8 SNP D302H is an independent
prognostic factor (Table S4 and S5 in S1 File)
Impact of SNPs on age at diagnosis and association with the stage
of the disease and MYCN status
We investigated the correlation between 21 SNPs and NB onset in a non-stratified
analysis (all subgroups) and also in an analysis stratified by MYCN status or by
clinical stage (localized vs. stage 4). CASP8 SNP D302H was not correlated to age
at diagnosis (Table S6 in S1 File). The same results were obtained for the
CASP8 SNP D302H (rs1045485) in Neuroblastoma
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remaining SNPs (data not shown). We also investigated whether CASP8 SNP
D302H or any of the 21 SNPs is associated with the MYCN status or stage of the
disease. CASP8 SNP D302H was not associated with MYCN status or stage of the
disease (Table S7 in S1 File). Similar results were obtained for the remaining SNPs
(data not shown).
CASP8 SNP D302H and expression of caspase 8
Since decreased expression of caspase 8 is a recurrent event in NB [18], we tested
whether CASP8 SNP D302H could affect the expression of caspase 8. We
measured caspase 8 mRNA expression in two independent cohorts of NB tumor
samples. Cohort 1 included 162 samples treated according to the International
Society of Pediatric Oncology Europe Neuroblastoma Group (SIOPEN, https://
www.siopen-r-net.org/). Cohort 2 included 161 samples from the Neuroblastoma
Research Consortium (NRC), which is a collaboration between several European
NB research groups. All samples from cohorts 1 and 2 were derived from patients
that had been included in the entire cohort of 500 patients analyzed in Table 1.
Table 2. Clinical characteristics of the patients.
Number Percentage
Age at diagnosis
.12 months 296 59.2
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We found that CASP8 SNP D302H had no effect on caspase 8 mRNA expression
levels, regardless of MYCN status or the stage of the disease (Table 4, Fig. 2).
Discussion
NB is a heterogeneous disease with a broad clinical spectrum ranging from
spontaneous regression and excellent outcome in low-risk patients to widely
disseminated disease and poor survival in high-risk patients. The phenomenon of
spontaneous NB regression has been attributed to successful delayed apoptosis of
tumor cells, whereas progression towards uncontrolled proliferation and tumor
formation largely reflects defects in the apoptotic process [19]. Evasion of growth
suppressors such as TP53 is a hallmark of tumor formation and development
[20], and functional inactivation of the TP53 pathway could be achieved either via
mutations in the TP53 gene itself or anywhere along the TP53 regulatory network.
Because TP53 is rarely mutated in NB at the time of diagnosis (,2%) [21], other
Fig. 1. Overall and event-free survival of NB patients by CASP8 SNP D302H. Comparison of Kaplan-
Meier survival curves between different genotypes of CASP8 SNP D302H. Overall survival of MYCN-
amplified NB patients (A), event-free survival of MYCN-amplified NB patients (B). Raw P-values were
calculated by the log rank test. q-values are adjusted p-values after Benjamini-Hochberg multiple testing
correction.
doi:10.1371/journal.pone.0114696.g001
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components of the TP53 pathway could be responsible for circumvention of this
fundamental antitumor barrier. Numerous reports have suggested that germline
alterations in TP53 and TP53 pathway genes are associated with cancer risk and
clinical outcomes [4]. Several SNPs that predispose to NB have been identified by
Table 3. Survival of NB patients by CASP8 D302H status.
Overall survival GG CC/CG
CASP D302H Dead Censored Dead Censored Chi-Square P-values q-values
All stages 88 321 32 59 6.57 0.0079 0.277
Stage 4 75 70 25 13 1.26 0.127 0.901
Stages (1,2,3,4s) 13 251 7 46 4.41 0.035 0.594
MNA 38 35 17 4 11.7 0.0006 0.049
MNN 50 286 15 55 1.11 0.251 0.901
Event-free survival GG CC/CG
CASP8 D302H Event Censored Event Censored Chi-Square P-values q-values
All stages 122 287 39 52 3.81 0.0456 0.638
Stage 4 88 57 29 9 1.4 0.136 0.901
Stages (1,2,3,4s) 34 230 10 43 0.834 0.355 0.901
MNA 44 29 19 2 13.4 0.0002 0.042
MNN 78 258 20 50 0.157 0.665 0.919
Raw P-value is calculated by Log Rank (Mantel-Cox) test.
q-value is the adjusted p-value after Benjamini-Hochberg multiple testing correction.
Censored: The patient was alive or did not have an event until the last date of follow-up.
MNA: MYCN-amplified.
MNN: MYCN not amplified.
doi:10.1371/journal.pone.0114696.t003
Table 4. Distribution of caspase-8 expression by CASP8 D302H.
Cohort 1 GG CC/CG
CASP8 D302H N Mean Rank N Mean Rank U P-values q-values
All stages 132 79.2 30 91.8 1670 0.184 0.897
Stage 4 30 18.9 7 19.5 102 0.894 0.974
Stages (1,2,3,4s) 102 60.8 23 72.7 951 0.156 0.897
MNA 23 13.4 4 17.5 32 0.372 0.897
MNN 109 26 26 25 1270 0.422 0.897
Cohort 2 GG CC/CG
CASP8 D302H N Mean Rank N Mean Rank U P-values q-values
All stages 127 80.6 33 82.7 2100 0.817 0.948
Stage 4 51 31.9 14 390 300 0.207 0.897
Stages (1,2,3,4s) 76 49.4 19 42.5 618 0.333 0.897
MNA 21 12.9 9 21.6 39.5 0.372 0.897
MNN 106 66.8 24 62.8 1250 0.639 0.916
Raw P-value is calculated by Mann-Whitney U test.
q-value is the adjusted p-value after Benjamini-Hochberg multiple testing correction.
doi:10.1371/journal.pone.0114696.t004
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genome-wide association studies (GWAS). The SNPs most highly associated with
increased NB susceptibility and poor outcome were found in HACE1 (rs4336470)
[22], LIN28 (rs17065417) [22, 23], BARD1 (rs6435862, rs3768716) [24], LMO1
(rs110419) [25], DUSP12 (rs1027702), DDX1 (rs2619046), IL31RA (rs10055201),
and HSD17B12 (rs11037575) [26]. However, despite the power of GWAS for
identifying new predisposing SNPs, these studies still lack the ability to identify all
SNPs and there is a high probability of false negatives [27]. Rather than choosing a
GWAS approach with complex data analysis, we decided to conduct a focused
study to examine particular SNPs in the TP53 pathway that are thought to
influence susceptibility to cancer [4, 8, 12–15]. Our study represents the largest
targeted SNPs study in a large cohort of 500 NB patients. We investigated the
association of 21 SNPs in fifteen TP53 pathway associated genes with the survival,
age at diagnosis, stage of the disease, and MYCN status of 500 NB patients. We did
multiple testing correction using Benjamini-Hochberg method and considered
only the q-values (corrected p-values) less than 0.05 as significant. Our results
showed that one SNP, CASP8 SNP D302H (rs1045485) was associated with worse
overall and event-free survival in NB patients with MYCN amplification. Of note,
we analyzed 41 representative blood samples from the patients in our cohort and
observed that all these patients have the same SNP status in their blood as in their
tumor (data not shown), indicating that CASP8 SNP D302H is a germline risk
factor for NB patients with MYCN amplification. CASP8 SNP D302H is a
missense variant located in exon 10 of the CASP8 gene. CASP8 encodes for
inactive procaspase 8 that is later activated by dimerization to form caspase 8.
Caspase 8 plays an important role in execution of the extrinsic cell death pathway
(death receptor-mediated killing) and is involved in several other cell signaling
pathways [28]. Down-regulation of caspase 8 is a well-characterized apoptotic
defect in NB tumors [18]. CASP8 is located on 2q33, a region frequently
associated with loss of heterozygosity (LOH) in NB [29]. Down-regulation of
caspase 8 can be achieved via deletion or epigenetic silencing, preferentially in
Fig. 2. Expression of caspase-8 by CASP8 SNP D302H. Comparison of caspase-8 expression between the different genotype groups of CASP8 SNP
D302H. Cohort 1 (A), Cohort 2 (B). P-values were calculated by the Mann-Whitney U test. q-values are adjusted p-values after Benjamini-Hochberg multiple
testing correction.
doi:10.1371/journal.pone.0114696.g002
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MYCN-amplified NB tumors [30]. A recent study has shown that loss of caspase 8
expression in a Th-MYCN/caspase-8 deleted mouse model significantly enhanced
development of advanced NB and metastasis to the bone marrow [31]. Although
these two events (MYCN amplification and reduced caspase 8 expression) are
closely related in NB, it has been shown that MYCN overexpression does not
affect the methylation status or expression of CASP8 [32]. We investigated the
effect of CASP8 SNP D302H on caspase 8 mRNA expression in two independent
cohorts. Our results showed that CASP8 SNP D302H had no effect on caspase 8
expression; being a non-synonymous SNP, it may therefore have a possible role in
the activation of procaspase 8 or in the interaction of caspase 8 with elements that
form the death-inducing signaling complex (DISC). CASP8 SNP D302H encodes
an amino acid residue that is localized on the external surface of procaspase 8 and
that could affect the processing of procaspase 8 or caspase-8 interaction with other
apoptosis regulators. However, until this is confirmed, the effect of this SNP on
caspase 8 activity remains elusive. The well-known MDM2 SNP309 was also
included in our targeted analysis of 21 SNPs. Previous studies reported an
association of this SNP with neuroblastoma [33, 34], and other cancers [13];
however, we have recently shown that this SNP is not associated with
neuroblastoma. Ethnicity of the studied populations, statistical power, or
genotyping data quality could be a reason for this discrepancy [35].
Conclusions
In conclusion our study shows that SNP D302H, a missense SNP in exon 10 of
CASP8 gene, is associated with worse overall survival and event-free survival in
NB patients with MYCN amplification.
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